🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› New York
Clinical trial register · United States · industry-sponsored

Clinical Trials in New York

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9109 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 19 Sep 2026, 04:27 UTC
9109
Studies in scope
industry-sponsored, all four open statuses
4946
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 113 Florida 107 Massachusetts 65 Georgia 62 Illinois 59
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca86 Janssen Research & Development, LLC52 Novartis Pharmaceuticals46 Pfizer46 Merck Sharp & Dohme LLC45 Clear sponsor filter
State
California113 Florida107 Massachusetts65 Georgia62 Illinois59
All 47 states
Target enrolment
to
46 of 9109 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
NCT07768371IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy
Novartis Pharmaceuticals
Phase 3
576
Alabama, Arizona, Arkansas, California, Maryland, Michigan, New Jersey, New York
2026-08-27
Recruiting
ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)
NCT07448610Spinal Muscular Atrophy
Novartis Pharmaceuticals
Phase 4
36
New York
2026-08-27
Recruiting
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
NCT07665437Hidradenitis Suppurativa
Novartis Pharmaceuticals
Phase 3
710
Arkansas, California, Illinois, Indiana, Nebraska, New York, Ohio, South Carolina
2026-07-10
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals
Phase 3
460
Connecticut, Florida, Georgia, Indiana, New Jersey, New York, Ohio, Texas
2026-06-16
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
Novartis Pharmaceuticals
Phase 2
50
New Jersey, New York, Ohio, Washington
2026-04-28
Recruiting
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177Non-segmental Vitiligo
Novartis Pharmaceuticals
Phase 2
210
Alabama, California, Florida, Indiana, Michigan, Nebraska, Nevada, New York
2026-03-09
Recruiting
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07441642Geographic Atrophy Secondary to Age-related Macular Degeneration
Novartis Pharmaceuticals
Phase 2
272
California, Florida, Massachusetts, New Jersey, New York, Pennsylvania, Texas
2026-03-09
Recruiting
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
NCT07091019Chronic Myelogenous Leukemia - Chronic Phase
Novartis Pharmaceuticals
Observational
1,000
Alabama, California, Connecticut, Florida, Illinois, Maryland, Missouri, New York
2025-12-17
Recruiting
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
NCT07217067Atrial Fibrillation
Novartis Pharmaceuticals
Phase 2
165
Mississippi, New Jersey, New York, North Carolina, Utah, Washington
2025-10-28
Recruiting
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
NCT06751238Juvenile Psoriatic Arthritis
Novartis Pharmaceuticals
Phase 1
20
California, Florida, Illinois, New York, North Carolina, Ohio, Oregon, Pennsylvania
2025-09-24
Recruiting
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT06858319Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis
Novartis Pharmaceuticals
Phase 3
220
Colorado, Florida, Iowa, New York, Tennessee, Texas
2025-07-28
Active, closed
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07047118Prostatic Cancer, Castration-Resistant
Novartis Pharmaceuticals
Phase 2
138
California, Colorado, Connecticut, Indiana, Massachusetts, Nebraska, New York, Pennsylvania
2025-07-03
Recruiting
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
NCT06711887Lupus Nephritis
Novartis Pharmaceuticals
Phase 3
348
New York
2025-05-19
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1/2
280
California, Florida, Massachusetts, Missouri, New York, Tennessee, Texas, Washington
2025-04-03
Recruiting
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
NCT06597019Familial Hypercholesterolemia - Heterozygous
Novartis Pharmaceuticals
Phase 3
60
California, District of Columbia, Florida, New York, Utah, Virginia, West Virginia
2024-12-09
Active, closed
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
NCT06643481Amyotrophic Lateral Sclerosis (ALS)
Novartis Pharmaceuticals
Phase 2
251
California, Florida, Georgia, Kansas, Massachusetts, Nebraska, New York, North Carolina
2024-10-17
Recruiting
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06470048Diffuse Cutaneous Systemic Sclerosis
Novartis Pharmaceuticals
Phase 2
200
Arizona, California, Florida, Illinois, Louisiana, Michigan, New York, Tennessee
2024-10-09
Recruiting
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
NCT06401356Hematologic Malignancy, Solid Tumor, Advanced Malignancies
Novartis Pharmaceuticals
Phase 3
50
California, Florida, Illinois, Michigan, New York
2024-08-13
Active, closed
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
NCT06379217Metastatic Neuroendocrine Prostate Cancer
Novartis Pharmaceuticals
Phase 1
31
Nebraska, New York
2024-07-29
Active, closed
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
NCT05739942Newly Diagnosed and Recurrent Glioblastoma
Novartis Pharmaceuticals
Phase 1
42
California, Colorado, Massachusetts, New York, Ohio, Utah
2024-05-15
Active, closed
Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)
NCT06155500Sickle Cell Disease
Novartis Pharmaceuticals
Phase 1
4
Illinois, New York, Tennessee
2024-04-16
Active, closed
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
NCT06004661Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
Phase 2
23
New York
2024-04-04
Active, closed
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
NCT05838768MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Novartis Pharmaceuticals
Phase 1
123
California, Massachusetts, New York, Texas
2023-06-27
Active, closed
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
NCT05552469Myeloid Diseases
Novartis Pharmaceuticals
Phase 1
71
California, Florida, Illinois, Maryland, Massachusetts, Minnesota, New York, Tennessee
2023-05-08
Recruiting
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
NCT05682378Heterozygous or Homozygous Familial Hypercholesterolemia
Novartis Pharmaceuticals
Phase 3
195
Florida, New York, Ohio, Pennsylvania, Utah
2023-02-10
Rows per page Showing 1–25 of 46
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-usa/state/new-york

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.